GlassScriptPhysician profile
David S Seminer
NPI 1619928983
$1,287.23
in general payments reported to CMS, 2019-2025
11 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $70.02 · 2021: $380 · 2022: $212 · 2023: $184 · 2024: $30.53 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $361 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $360.70 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $457.79 | 2021-2024 | Ubrelvy, Qulipta |
| Biohaven Pharmaceuticals, INC. | $212.20 | 2021 | |
| Pfizer INC. | $146.14 | 2025 | |
| Amgen INC. | $121.61 | 2019 | |
| Emd Serono, INC. | $113.99 | 2019 | |
| Axsome Therapeutics, INC. | $111.88 | 2023 | Auvelity |
| Allergan, INC. | $58.79 | 2020 | |
| Ucb, INC. | $26.23 | 2020-2025 | Rystiggo |
| Supernus Pharmaceuticals, INC. | $14.43 | 2019 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Seminer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.